Two of the newsletter industry's leading growth stock advisors remain bullish on the prospects of online retailer Amazon.com (NASDAQ: AMZN), based on growth in not only online retailing but new market areas ranging from the Kindle e-reader to cloud computing.

Mike Cintolo, editor of The Cabot Top Ten Report, explains, "Amazon.com recently blew away earnings expectations." Meanwhile, Alexander Green, investment director at The Oxford Club, says, "In our view, the best lies ahead for the company." Here are their reviews.

Mike Cintolo continues, "Amazon announced that its Kindle e-book reader is now its most popular selling item, both in units and in dollars. That led to a big acceleration in revenue growth (28%, the fastest in five quarters), while earnings leaped 67%.

"If you use a mobile phone with a camera, thank Tessera (NASDAQ: TSRA)," says Mike Cintolo in the Cabot Top Ten Report. "When it comes to miniaturization, Tessera is the go-to company."

"Tessera is one of the companies that drove the price of camera components down by miniaturizing them and combining them on a single chip.

"You'll find its technology in MP3 players, video games, wireless phones, computers and numerous other products where companies are forever working to design products smaller and manufacture them more cheaply.

This post is part of a featured report on stocks in the Chinese online gaming sector.

"One lesson we learned long ago is that it often pays to recognize stocks showing unusual strength -- one such stock is NetEase (NASDAQ: NTES)," says Mike Cintolo in The Cabot Market Letter.

"In terms of stocks, NetEase is showing unusual strength. The stock started moving ahead in a powerful manner as soon as (actually a bit before) the market bottomed in March.

"In fact, NTES recently notched nine straight up weeks, all on above-average volume, breaking out of a three-year base in the process!

One month ago, we featured a special report featuring the favorite China-based stocks among financial newsletter advisors. Since then, the 14 stocks covered in the report have risen an average of more than 15%.

The performance of these stocks -- along with the overall China market -- has far exceeded the 3% gain in the S&P 500 index over the same time period. That report can be viewed here.

Despite these gains, many of the leading advisors remain bullish on China; in particular, several have recently focused on the online gaming sector in Asia. Indeed, Timothy Lutts notes that while the video game market in the U.S. is slowing, the video game market in China is expected to show 20%+ annual growth in coming year.

This post is part of a seven article report -- Food for thought: Best bets in food & beverage stocks.

"We think there's enormous potential for profit as Whole Foods Market (NASDAQ: WFMI) recovers from its deeply oversold position," says Mike Cintolo. Here's the latest from The Cabot Top Ten report.

"Whole Foods is the fourth-largest grocery store operator in the U.S., a rank it's achieved, among far older competitors, by competing not on price but on quality. In particular, Whole Foods has succeeded by satisfying shoppers' demand for healthy, earth-friendly organic foods.

This post is part of a seven article report -- Food for thought: Best bets in food & beverage stocks.

"The fast-casual restaurant category is sizzling as consumers trim their eating budgets; this trend is helping Panera Bread (NASDAQ: PNRA)," says Michael Cintolo in The Cabot Top Ten Report.

"In restaurant parlance, 'fast-casual' eateries are higher priced than fast-food chains such as McDonald's and KFC, but cheaper than casual dining restaurants such as Applebee's and Denny's.

In a difficult economic environment, it is often wise for investors to consider stocks in more defensive and relatively recession-resistant sectors. And one such area is food and beverage stocks.

As the long-standing market maxim goes, consumers can pull back on spending for vacations, remodeling, and new cars, but they still need to eat and drink.

In that light, I turned to nine leading newsletter advisors who serve up their current favorite ideas in the food and beverage sector:

"Illumina (NASDAQ: ILMN) makes the Genome Analyzer, which is the workhorse of the genetic medicine revolution," says growth expert Mike Cintolo in The Cabot Top Ten Report.

"The Illumina Genome Analyzer is used by genomic research centers, academic institutions, agriculture and livestock companies, pharmaceutical companies, clinical research organizations and biotechnology companies all over the world.

"In the fourth quarter of 2008, for example, the company launched the In? nium HD HumanCytoSNP-12 BeadChip, a 12 sample BeadChip priced as low as $125 per sample that enables researchers to analyze nearly 300,000 genetic markers per sample.

Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.

In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical products makers to medical services firms focused on increasing health care efficiency and early disease detection.

Mike Cintolo, editor of The Cabot Market Letter, thinks Myriad Genetics (NASDAQ: MYGN) could be a "big winner in 2009," The company is a lead in the new field of cancer predisposition testing. For Mike's full report, read Top Stock Picks '09: Myriad Genetics.

Chuck Carlson, editor of The DRIP Investor, sees both quality and potential in Bristol-Myers Squibb (NYSE: BMY). For Chuck's full report, read Top Stock Picks '09: Bristol-Myers Squibb.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"My top idea for 2009 is Myriad Genetics (NASDAQ: MYGN)," says Mike Cintolo. In The Cabot Market Letter, he looks at "the leader in the new field of cancer predisposition testing."

"Myriad Genetics five tests on the market (covering colon, breast, ovarian, and skin cancer) that tell a patient if his genes make it more likely that he'll get various types of cancer.

"During the past few quarters, revenues from these tests have risen at a 50% annual clip, and there's no sign of that slowing down.

"The company also has a pharmaceutical division, but it's going to spin that off sometime in 2009. That should be a big positive, as the drug development division carries good potential, but also big-time costs. Once the cancer predisposition testing division is on its own, much of that revenue growth is going to fall to the bottom line.